Search

Glioblastoma multiforme (GBM) is the most prevalent, treatment-resistant, and fatal form of brain malignancy. It is characterized by genetic heterogeneity, and an infiltrative nature, and GBM treatment is highly challenging. Despite multimodal therapies, clinicians lack efficient prognostic and predictive markers. Therefore, new insights into GBM management are urgently needed to increase the chance of therapeutic success. Circulating miRNAs (miRs) are important regulators of cancer progression and are potentially useful for GBM diagnosis and treatment. This study investigated how miR-29a, miR-106a, and miR-200a affect the prognosis of GBM patients. This study was conducted on 25 GBM patients and 20 healthy volunteers as a control group. The expression levels of target miRs were analyzed pre- and post-treatment using qRT-PCR and evaluated in relation to both clinical GBM criteria and the patient's survival modes. The diagnostic efficacy of target miRs was assessed using the receiver operating characteristic (ROC) curve. MiRs levels showed significant differences among the enrolled participants. All investigated miRs were significantly elevated in GBM patients with non-frontal lesions. Only miR-200a showed a significant difference in GBM patients older than 60 years with a tumor size ≥ 5 mm. Regarding miR-106a, a significant difference was detected based on the surgical strategy and use of an Eastern Cooperative Oncology Group (ECOG) performance status equal to 2. For miR-29a, a significant upregulation was detected according to the surgical strategy. All post-treatment miRs levels in GBM patients were significantly downregulated. In conclusion, circulating miRs revealed a significant role in predicting GBM patient treatment outcomes providing valuable insights for personalized therapeutic strategies. [ABSTRACT FROM AUTHOR]

Aims Methods Results Conclusion Clinicaltrial.gov registration ID Owing to its underlying inflammatory nature, atherosclerotic cardiovascular disease remains the leading global cause of mortality, particularly post‐ST‐elevation myocardial infarction (STEMI), a condition with significant risk for further cardiovascular events and mortality. This study aimed to investigate colchicine's effect on inflammation, cardiac remodelling and atherosclerotic risk in STEMI patients.We conducted a randomized controlled study on 88 STEMI patients undergoing percutaneous coronary intervention. Eligible patients were randomly assigned to 1 of 2 groups. The control group received the guideline‐directed medical therapy for STEMI, and the test group received guideline‐directed medical therapy and 0.5 mg colchicine twice daily for 3 months. The soluble suppressor of tumorigenicity (sST2), interleukin‐1β, lipid profile parameters, triglyceride (TG)/high‐density lipoprotein (HDL‐C) ratio levels and left ventricular ejection fraction were evaluated for patients at baseline and the end of the 3 months.No significant effects were reported for colchicine on sST2, interleukin‐1β levels or left ventricular ejection fraction. Colchicine significantly lowered TG levels vs. controls, 134 (46–353) vs. 176 (72–825) respectively, P = .02, as well as TG/HDL‐C ratio levels, 4.16 (2.75–5.24) vs. 5.11 (3.51–8.33),` respectively, P = .024. sST2 levels of the studied cohort were positively correlated with their TG/HDL‐C ratio levels (R = .459, P < .001) at the end of follow‐up.Our study highlights a promising impact of colchicine on atherosclerosis and cardiac remodelling factors in STEMI patients. Colchicine significantly reduced TG levels and TG/HDL‐C ratio and was safe and well tolerated. Larger long‐term studies powered to assess clinical outcomes of remodelling are necessary to confirm its beneficial effects in STEMI.NCT06054100. [ABSTRACT FROM AUTHOR]